Medrio aims to unify clinical trial tools to ease complexity for biotech firms

Mike Novotny, founder and CEO of Medrio, says that funding cycles, growing study complexity and fragmented technology are slowing clinical research, especially for small and midsize life‑science companies.

He notes that trial teams often have to stitch together EDC, ePRO, RTSM, CTMS and eTMF systems using integrations, spreadsheets and manual steps.

To address this, Medrio is developing a more unified product suite that links these functions, giving teams easier access to study information.

The company is also using a customer‑listening approach and an early adopter program to shape its new CTMS based on user feedback.